Bahrain first to approve Evusheld

Bahrain has approved the emergency use of AstraZeneca’s anti-Covid drug Evusheld.

The kingdom has become the first country to authorise the drug, which will be available to adults 18 years and above, who are immunocompromised or who are taking immunosuppressive drugs or individuals with occupations that put them at risk of infection.

The decision follows the evaluation of data provided by the manufacturer, carried out by the National Health Regulatory Authority’s Pharmaceutical Products Regulation department.

Evusheld is made from a mixture of two antibodies, which achieved a “statistically significant decrease in cases of acute or fatal Covid-19 infection” in patients who were not admitted to hospital and those with symptoms ranging from mild to moderate.




Share this page Share on FacebookShare on TwitterShare on Linkedin

Discover the 'Made in France à Bahrain' Guide

'Made in France à Bahrain' - Edition 2021
is YOUR guide to the economic presence in Bahrain. Click here to view the online guide